Korean study monitors new multiple myeloma drug in Real-World use
NCT ID NCT06581848
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is monitoring the safety and effectiveness of the drug Elranatamab in 150 Korean adults with multiple myeloma that has returned or not responded to at least three prior treatments. Researchers are tracking side effects and how well the drug controls the cancer in everyday clinical practice. The goal is to gather real-world data to better understand the drug's risks and benefits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Seoul, South Korea